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S-100B.  Conclusion: We conclude that follow-up investi-
gations and calculation of ratios is a useful tool in the dif-
ferential diagnosis of CJD. Variations in this pattern were 
observed in single cases. 
 Copyright © 2005 S. Karger AG, Basel 
 Introduction 
 Up to now, the intra vitam diagnosis of Creutzfeldt-
Jakob disease (CJD) has been made according to clinical 
and electroencephalographic criteria  [1] . The clinical di-
agnosis of CJD can be supported by biochemical analysis 
of cerebrospinal fl uid (CSF) for tau protein  [2–5] , S-100B 
 [6, 7] or 14-3-3 protein  [8–10] . So far, only the 14-3-3 im-
munoblot is included in the diagnostic criteria  [11] , de-
spite the fact that the other surrogate markers also have 
a high differential diagnostic potential and that the diag-
nostic accuracy of 14-3-3 proteins was challenged recent-
ly  [6, 12–15] . The fi nal diagnosis of CJD can only be made 
neuropathologically by demonstrating the pathological 
isoform of the prion protein (PrP Sc )  [16] . Routine detec-
tion of PrP Sc  outside the brain for an early in vivo diag-
nosis of sporadic CJD has yet to become established. First 
attempts to detect PrP aggregates were made using fl uo-
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 Abstract 
 Background: S-100B and tau protein have a high differ-
ential diagnostic potential for the diagnosis of Creutzfeldt-
Jakob disease (CJD). So far there has been only limited 
information available about the dynamics of these pa-
rameters in the cerebrospinal fl uid (CSF). However, there 
is a special interest in fi nding biochemical markers to 
monitor disease progression for differential diagnosis 
and treatment.  Patients and Methods: We analyzed CSF 
of 45 patients with CJD and of 45 patients with other 
neurological diseases for tau protein and S-100B in a fol-
low-up setting. All diagnoses of CJD were later neuro-
pathologically verifi ed. A ratio between tau protein dif-
ferences and the time between lumbar puncture was 
calculated. The same was done for S-100B.  Results: Tau 
protein levels of 34 cases were above the cut-off level for 
CJD ( 1 1,300 pg/ml) in the fi rst CSF sample. In 7 of 11 pa-
tients with lower tau levels in the fi rst CSF sample, tau 
levels rose. The above-mentioned ratio was signifi cantly 
higher in the CJD group than in the group with other neu-
rological diseases. Similar results were obtained for
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rescence-correlated spectroscopy  [17] . The situation for 
patients with new variant CJD (vCJD) is different as a 
pathological isoform also was detected in the tonsils of 
these patients  [18] . 
 Although CJD is rare, it is often considered in the dif-
ferential diagnosis, especially at the beginning of a de-
menting process. The measurement of tau protein and 
amyloid beta peptides in CSF has gained wide acceptance 
in the differential diagnosis of dementias  [19, 20] . But up 
to now there is only limited information available on fol-
low-up levels of these markers, especially in patients with 
a differential diagnosis of CJD. Such information should 
help to improve diagnostic accuracy for unclear cases. On 
the other hand, follow-up investigations of biological 
markers might be an alternative tool to monitor effects of 
upcoming therapeutic approaches for CJD or other neu-
rodegenerative diseases like Alzheimer’s disease (AD) 
 [21, 22] . 
 In our study we measured the levels of tau protein and 
S-100B as for these markers quantitative assays with ac-
ceptable variation coeffi cients are available. In previous 
studies, optimal cut-off levels for tau protein and S-100B 
for the diagnosis of CJD were already obtained  [2, 4, 6, 
7] . 
 Patients and Methods 
 We analyzed CSF of 90 patients with a differential diagnosis of 
CJD. Forty-fi ve of these patients were later neuropathologically 
confi rmed as CJD cases. In the remaining 45 patients, other neu-
rological diseases (OND) were diagnosed. Tau protein was mea-
sured repetitively in CSF of 78 patients and S-100B protein was 
measured in CSF of 51 patients. According to the clinical criteria, 
all suspected cases of CJD were classifi ed as ‘probable’, ‘possible’ 
or ‘other’ cases  [11, 23, 24] . Samples from these patients were ob-
tained from the CSF bank of the German CJD counseling labora-
tory.  
 The diagnoses in the OND group were as follows: 8 patients with 
AD, 4 patients with corticobasal degeneration (CBD), 4 patients 
with vascular dementia (VD), 3 hepatic encephalopathies, 2 with 
neoplastic diseases of the brain, 2 patients with frontotemporal de-
mentia (FTD), 2 with depression, 2 with epilepsy, 1 patient with 
Lewy body dementia (LBD), 1 patients with motor neuron disease, 
1 with progressive subcortical gliosis (Neumann-Cohns disease), 1 
with uremic encephalopathy, 1 with mitochondrial encephalopa-
thy, 1 with Hashimoto’s encephalopathy and 12 with infl amma-
tory diseases of the nervous system.  
 Neuropathology 
 All 45 diagnoses of CJD were neuropathologically confi rmed 
using standard methods  [16] . Additionally, prion protein typing 
was done and polymorphism at codon 129 was determined  [25] . 
 Tau Protein, S-100B and 14-3-3 Protein Measurement 
 Tau protein and S-100B protein were measured with commer-
cially available assays (Innogenetics, Ghent and Byk-Sangtec,
Dietzenbach)  [20, 26] . Normal levels of tau protein were below
420 pg/ml. The optimal cut-off level for CJD patients was above 
1,300 pg/ml  [2] . In a control group, S-100B levels were below
2.2 ng/ml and above 4.2 ng/ml in the CJD patients  [7] . The 14-3-3 
immunoblot was performed on all samples according to the previ-
ously published standard method  [8] . 
 Statistical Analysis 
 The comparison of the tau level and S-100B level between sub-
groups of the study population was based on nonparametric tests 
(the Wilcoxon-Mann-Whitney U test for independent comparisons 
and the Wilcoxon signed-rank test for dependent comparisons).  
 Marker Difference to Time Difference Ratio 
 As we aimed to investigate the dynamics of tau protein and S-
100B in the follow-up we calculated a marker difference to time 
difference ratio (MTR): e.g. (level of tau protein at lumbar puncture 
(LP) 1) – (level of tau protein at LP 2)/(time difference of LP in 
days). 
 Results 
 Follow-up data were available for 45 patients with 
neuropathologically confi rmed CJD and 45 patients with 
OND. Patient characteristics (gender, age) are given in 
 table 1 . Times between LPs ranged between 2 and 546 
days (median: 31 days) in the CJD group and between 1 
and 1,252 days (median: 33; p = 0.9).  
 Comparison of Tau Protein Levels in CJD and OND 
 We analyzed 45 patients with CJD. Twenty-six pa-
tients were classifi ed as ‘probable’ CJD, 9 as ‘possible’ and 
4 were initially classifi ed as ‘other’ cases. Six patients suf-
fered from genetic CJD. Median tau protein level at the 
fi rst LP was 2,757 pg/ml (range 75–21,964 pg/ml) and 
3,443 pg/ml (range 75–32,795 pg/ml) at the second LP 
 Table 1. Patient characteristics  
Diagnosis Male/female Age, years
median range
CJD
Sporadic 16/23 (39) 61 19–77
Genetic 3/3 (6) 62 57–77
OND 22/23 (4) 60 27–80
Neuropathologically confi rmed cases are shown in parenthe-
ses.
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 (fi g. 1a) . Tau protein levels were signifi cantly higher at the 
second LP (p = 0.003). Thirty-four cases (75%) had levels 
above the previously established cut-off level for the diag-
nosis of CJD ( 1 1,300 pg/ml) in the fi rst CSF sample. Tau 
protein rose in 29 cases at the second LP (64%). Tau pro-
tein levels rose especially in 7 cases among the 11 patients 
who had tau protein levels below 1,300 pg/ml in the fi rst 
LP. Four of these rose above the cut-off level and 2 came 
close to the established cut-off level (1,157 and 1,172 pg/
ml). 
 The clinical presentation of a CJD patient strongly de-
pends on the PrP type and the polymorphism of codon 
129. Typing of the 39 defi nite sporadic cases according to 
Parchi  [25] was available on 22 cases. The distribution of 
the polymorphism at codon129 and prion protein type 
was as follows: methionine/methionine PrP Sc  type 1: 9 cas-
es; methionine/methionine PrP Sc  type 2: 1 case; methio-
nine/valine PrP Sc  type 1: 2 cases; methionine/valine PrP Sc  
type 2: 4 cases; valine/valine PrP Sc  type 1: 1 case; valine/
valine PrP Sc  type 2: 5 cases. There were no relevant differ-
ences of tau protein follow-up measurement within these 
subgroups. 
 Four of the 45 CJD (9%) patients were initially clini-
cally diagnosed with other diseases. Tau protein was 
above the cut-off level for CJD in 3 patients and even rose 
in 2 patients. One patient had low levels of tau protein at 
both LPs. This patient had a valine/valine polymorphism 
at codon 129. 
 Genetic CJD: In 3 patients a fatal familial insomnia 
(FFI) was diagnosed: 2 patients had an insert mutation 
and 1 patient an E200K mutation of the prion protein 
gene. S-100B levels rose markedly in all genetic patients. 
Tau protein levels rose in 3 patients, but stayed below the 
cut-off levels in 2 (both FFI cases). 
 Forty-four of forty-fi ve patients with OND were ana-
lyzed. The tau protein levels reached a median value of 
702 pg/ml (range 75–22,218 pg/ml) in the fi rst LP and 
650 pg/ml (median; range 75–18,285 pg/ml) in the second 
LP. There was no signifi cant difference between the fi rst 
and second LP (p = 0.53). Sixteen patients (36%) were 
 Fig. 1. Tau protein ( a ) and S-100B ( b ) levels (both at logarithmic scale) at fi rst and second LP. Dashed lines rep-
resent cut-off levels for tau protein (1,300 pg/ml) and S-100B (4.2 ng/ml). Individual values and means  8 SEM 
(thick horizontal and vertical lines). 
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above the cut-off level in the fi rst LP and 12 (27%) in the 
second LP. In 4 of these 16 patients, tau protein levels 
decreased below the cut-off level for CJD.  
 Comparison of MTR in CJD and OND 
 MTRs between the CJD and OND group were signifi -
cantly different, with higher values in the CJD group
(p  ! 0.05)  (fi g. 2a) . The median MTR  of CJD between 
both LPs was 9 pg/ml/day (range –1,425 and 9,214 pg/
ml/day). The mean MTR for the OND group was –1 pg/
ml/day (range: –388.9 and 164.6 pg/ml/day). Patients 
with multiple infarct syndromes had a positive/increas-
ing gradient (median 292 pg/ml/day). Patients with AD 
(MTR: median –1.9 pg/ml/day), frontotemporal demen-
tia (MTR: median –1.7 pg/ml/day) and corticobasal de-
generation (MTR: median –2 pg/ml/day) had decreasing 
tau levels which is represented by a negative MTR. Fur-
thermore patients with neoplasias of the brain had de-
creasing MRTs (median –6 pg/ml/day). 
 Comparison of S-100B Levels in CJD and OND 
 We analyzed 31 patients with CJD (18 patients classi-
fi ed as probable, 7 as possible CJD, 3 as other disease, 6 
as genetic CJD). All diagnoses of CJD  were neuropatho-
logically confi rmed. S-100B levels ranged between 1  and 
19 ng/ml in the fi rst LP (median: 5.3 ng/ml) and between 
1.9 and 37.8 ng/ml (median: 7.8 ng/ml) in the second LP. 
S-100B levels were signifi cantly higher at the second LP 
(p = 0.0007)  (fi g. 1b) . 
 In 21 (68%) of these 31 patients, S-100B protein was 
above the cut-off level for CJD (4.2 ng/ml) and in 10 
(32%) below the cut-off level. In the second LP , S-100B 
increased in 27 cases. Among the 10 patients with S-100B 
protein levels below 4.2 ng/ml, the S-100B protein levels 
of 9 patients had risen in the second LP. In 5 of these pa-
tients, they had risen above the cut-off level.  
 S-100 levels of 3 of the CJD patients with an initial 
diagnosis of ‘other disease’ were available. In the fi rst LP 
of 2  patients, levels below the cut-off level were mea-
sured. In all 3 patients, the S-100B level had risen. Two 
patients then had levels above the cut-off level. 
 We analyzed the S-100B levels of 28 patients of the 
OND group. The S-100B levels reached values between 
0.9  and 23.8 ng/ml (median: 2.1 ng/ml) in the fi rst sample 
and levels between 1.1 and 26.1 ng/ml (median: 2.6 ng/
ml) in the second sample. Levels of S-100B were signifi -
cantly higher in the second LP (p = 0.018). Three patients 
(11%) had levels above the cut-off level in the fi rst LP and 
6 (21%) in the second LP. The S-100B levels of 1 of these 
patients decreased to below the cut-off levels for CJD.  
 Follow-Up Investigation of S-100B in CJD and OND 
 The MTRs between CJD and OND group for S-100B 
were signifi cantly different (p  ! 0.02)  (fi g. 2b) with higher 
 Fig. 2. Differences of tau protein ( a ) and S-
100B protein ( b ) in relation to the follow-up 
time point expressed as MTR. 
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values in the CJD group. The MTRs of the CJD group 
ranged between –0.93 and 3.21 ng/ml/day (median: 0.06 
ng/ml/day), whereas in the OND group they ranged be-
tween –0.33 and 0.23 ng/ml/day (median: 0.01 ng/ml/
day). 
 Slightly increasing levels of S-100B were observed in 
AD (MTR, median 0.016 ng/ml/day), corticobasal degen-
eration (MTR, median 0.01 ng/ml/day), infectious dis-
eases (MTR, median: 0.019 ng/ml/day), hepatic encepha-
lopathy (MTR, median: 0.02 ng/ml/day). 
 Detailed Description of the OND Group 
 Alzheimer’s Disease 
 The diagnoses of 3 out of the 8 patients with AD were 
neuropathologically confi rmed. In 2 patients (25%), the 
levels of tau protein were above the cut-off level in the 
fi rst LP. In 1 out of 6 patients with AD the S-100B-level 
was above the cut-off level in the fi rst LP. In the second 
LP of this patient the S-100B level even increased, while 
the tau protein level remained stable. In the second LP of 
2 of the other 5 patients S-100B rose above the cut-off 
level for CJD, whereas the level of tau protein remained 
stable and was within the typical range for AD. 14-3-3 
assay was positive in 3 samples of the fi rst LP.  
 Corticobasal Ganglionic Degeneration 
 We investigated 4 patients with CBD. In all samples 
the levels of tau protein and S-100B protein were below 
the cut-off level for CJD. In 1 patient tau protein rose in 
the second LP (778–1,130 pg/ml). In 3 patients the S-
100B level rose without reaching the cut-off level for CJD. 
In 1 patient the 14-3-3 assay was positive in the fi rst LP 
(tau protein 483 pg/ml, S-100B 2.15 ng/ml). 
 Vascular Dementia  
 In the CSF of 2 out of 4 patients the tau protein was 
above the cut-off level and increased in the follow-up in-
vestigation. In 1 of the 2 patients S-100B rose from
2.6 ng/ml above the cut-off level to 8.1 ng/ml (tau protein 
1,849 to 10,368 pg/ml). A decline was observed in only 1 
case. The period of time between these LPs ranged from 
8 to 53 days. With one exception 14-3-3 assay was posi-
tive in all CSF samples. 
 Frontotemporal Dementia  
 Two patients with FTD were investigated. Tau protein 
levels of these patients were within the normal range in 
the fi rst and second LP. S-100B levels were below the cut-
off level for CJD. In neither of these samples 14-3-3 pro-
teins were detected. 
 Miscellaneous Neurodegenerative Disease 
 Only 1 patient with LBD was investigated in the fol-
low-up. Tau protein and S-100B protein in both LPs were 
in the normal range, whereas 14-3-3 assay was positive in 
the fi rst sample. 
 The patient with progressive subcortical gliosis (Neu-
mann’s disease) presented with a tau protein level above 
the cut-off level in the fi rst and in the follow-up investiga-
tion (3,160 and 2,621 pg/ml) after 26 days. S-100B-levels 
remained within the normal range.14-3-3 assay was al-
ways positive. 
 The levels for tau protein and S-100B were within the 
normal range for the patient suffering from motor neuron 
disease and the patient with mitochondrial encephalopa-
thy. 
 Infl ammation of the Central Nervous System and 
Hashimoto’s Encephalopathy 
 Seven patients with an acute infl ammation of the CNS 
and 5 patients with a chronic infl ammation of the CNS 
were analyzed. Tau protein was above the cut-off level in 
3 out of 7 patients with acute infl ammations and in 2 out 
of 5 with chronic infl ammation in the fi rst LP. Tau levels 
declined in only 2 patients (from 2,336  to 1,651 pg/ml 
and from 22,218 to 3,549 pg/ml). S-100B increased in 5 
out of 6 available patients. In almost all samples the 14-
3-3 assay was positive. 
 The patient with Hashimoto’s encephalopathy had 
normal levels of tau protein. S-100B levels rose from nor-
mal to 5.1 ng/ml after 423 days.  
 Hepatic Encephalopathy and Uremic 
Encephalopathy 
 We analyzed 3 patients with hepatic encephalopathy 
caused by liver cirrhosis. Two patients had levels above 
the cut-off level for CJD. In 1 patients the tau protein 
level dropped from 2,825 to 750 pg/ml within 70 days. In 
this patient 14-3-3 proteins were detected in both LPs. 
The other patient with elevated levels had constantly high 
levels (1,662–1,416 pg/ml). Levels of S-100B were not 
elevated (values only for 1 patient). The patient with ure-
mic encephalopathy exhibited with very high and increas-
ing tau protein levels and a positive 14-3-3 immunoblot. 
S-100B protein stayed within the normal range. 
 Epilepsy 
 Two patients suffering from epilepsy were investigated 
for tau protein. In one sample tau protein was initially 
above the cut-off level and dropped below in the follow-
up investigation. In both samples 14-3-3 assay was nega-
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tive. In the other patient tau protein levels rose from 604 
to 3,088 pg/ml within 15 days and dropped again to
136 pg/ml after again 115 days. In all of these samples 
14-3-3 assay was positive. None of these samples were 
investigated for S-100B. 
 Neoplasia 
 We analyzed the CSF of 2 patients with neoplastic dis-
eases. One case showed an elevated tau protein level with 
nearly unchanged values (1,380 and 1,433 pg/ml). S-100B 
level in this patient was only slightly elevated and dropped 
in the second LP. 14-3-3 assay was negative in both sam-
ples. The second patient had increased levels of tau pro-
tein (1,843 pg/ml) and a positive 14-3-3 assay, whereas 
the S-100B level was in the normal range. In the follow-
up investigation tau protein decreased to 345 pg/ml and 
14-3-3 assay was negative. 
 Depression 
 All markers were within the normal range in both pa-
tients. 
 Discussion 
 Measurement of tau protein and S-100B has a high 
diagnostic impact in the differential diagnosis of CJD. 
Sensitivities and specifi cities of about 90% were reached 
 [2, 4–7] . In the vast majority of studies nondemented 
control patients have tau protein levels below 420 pg/ml. 
Patients with neurodegenerative disease such as AD have 
levels between 420 and 800 pg/ml, whereas patients with 
CJD have levels above 1,300 pg/ml. The situation for the 
astroglial marker S-100B is quite similar although not as 
many studies for this protein have been published  [22] . 
Nondemented patients have levels below 2.2 ng/ml, some 
patients with other neurodegenerative diseases have ele-
vated levels and patients with CJD have S-100B levels 
above 4.2 ng/ml. In some cases the clinical diagnosis of 
CJD was challenged and a second LP was done. We ana-
lyzed all CSF samples of patients with a differential diag-
nosis of CJD and from whom more than one sample was 
available. CSF was sampled over the last 5 years in our 
counseling laboratory for CJD. During that time nearly 
2,500 samples were analyzed for patients with a differen-
tial diagnosis of CJD but repeat samples were available 
only for 90 patients (45 CJD, 45 OND). 
 As the time of the second LP is determined by the 
treating physician, time intervals varied between 1 and 
1,252 days. In an independent comparison we could show 
that for the individual CJD patients a signifi cant rise of 
tau protein and S-100B protein occurred. For the OND 
group only a just signifi cant increase of S-100B was ob-
served, whereas tau protein was not signifi cantly differ-
ent. The MTR clarifi es this observation. 
 From our investigation we conclude that patients with 
CJD have mainly increasing levels of S-100B and tau pro-
tein in the follow-up investigation. The S-100B increase 
might represent an ongoing astroglial activation and pos-
sible destruction, whereas the increase of tau protein 
might represent ongoing neuronal loss. In an anecdotal 
observation of 3 CJD cases a decrease of S-100B was de-
scribed at later stages  [27] . This was only rarely observed 
in our group. Nor were decreasing levels of tau protein 
often observed. At very advanced stages of CJD the levels 
may still decrease; however this was not observed in our 
study.  
 We further conclude that in other neurodegenerative 
diseases S-100B and tau protein remain mainly stable or 
show only a mild increase. This fi nding might be due to 
the much slower time course of these diseases. In infl am-
matory diseases S-100B and tau protein levels might even 
rise as in CJD. However, these diseases are usually easier 
to exclude by other clinical fi ndings than neurodegenera-
tive diseases like AD. 
 Since only immunoblot was available for 14-3-3 pro-
tein measurements, a comparison of levels is hardly pos-
sible and is only of limited use for the follow-up. We sup-
pose that repetitive analysis of this marker at well-defi ned 
times might be useful to monitor disease progression to 
investigate possible therapeutic effects in a group com-
parison. However, as demonstrated by our analysis, it will 
not be possible to predict the progression for an individ-
ual case as follow-up investigations vary from one patient 
to patient. 
 The challenge for the diagnosis of CJD is the early and 
differential diagnosis and it seems that repetitive LPs pro-
vide a better differential diagnosis. It will have to be elu-
cidated whether the measurement of additional markers 
such as phospho-tau or the amyloid beta-peptide pattern 
will yield even better results  [5, 28, 29] . 
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